Abstract
A series of phenyl alkyl ketone derivatives based phosphodiesterase 4 (PDE4) inhibitors was subjected to 2D Quantitative Structure–Activity Relationships (2D QSAR) and Hologram Quantitative Structure–Activity Relationship (HQSAR) studies. The dataset was divided into training and test sets by applying K-means clustering, and 2D QSAR models were established using stepwise linear regression analysis, replacement method and enhanced replacement methods. The models obtained demonstrated high correlation coefficient (R2=0.8374) and low standard deviation (S=0.4442). The robustness of models was confirmed using leave one out cross validation (R2 cv=0.7189), Y scrambling (R2=0.3640), and by test set prediction (R2 pred=0.6867). Topological, steric, electronic and electrotopological descriptors of phenyl alkyl ketone derivatives showed good correlation with the PDE4 inhibitory activity. HQSAR models were established using various fragment sizes, hologram lengths and fragment types. The top HQSAR model was justified by high R2 value of 0.973 and R2 cv value of 0.641. New molecules were designed based on these results and the activity was predicted using the established models.
Keywords: cAMP, cGMP, HQSAR, Phosphodiesterase, QSAR, Y scrambling.
Current Enzyme Inhibition
Title:Quantitative Structure Activity Relationship and Design of Phenyl Alkyl Ketone Derivatives as Inhibitors of Phosphodiesterase 4
Volume: 10 Issue: 1
Author(s): Anand Gaurav, Vertika Gautam and Ranjit Singh
Affiliation:
Keywords: cAMP, cGMP, HQSAR, Phosphodiesterase, QSAR, Y scrambling.
Abstract: A series of phenyl alkyl ketone derivatives based phosphodiesterase 4 (PDE4) inhibitors was subjected to 2D Quantitative Structure–Activity Relationships (2D QSAR) and Hologram Quantitative Structure–Activity Relationship (HQSAR) studies. The dataset was divided into training and test sets by applying K-means clustering, and 2D QSAR models were established using stepwise linear regression analysis, replacement method and enhanced replacement methods. The models obtained demonstrated high correlation coefficient (R2=0.8374) and low standard deviation (S=0.4442). The robustness of models was confirmed using leave one out cross validation (R2 cv=0.7189), Y scrambling (R2=0.3640), and by test set prediction (R2 pred=0.6867). Topological, steric, electronic and electrotopological descriptors of phenyl alkyl ketone derivatives showed good correlation with the PDE4 inhibitory activity. HQSAR models were established using various fragment sizes, hologram lengths and fragment types. The top HQSAR model was justified by high R2 value of 0.973 and R2 cv value of 0.641. New molecules were designed based on these results and the activity was predicted using the established models.
Export Options
About this article
Cite this article as:
Gaurav Anand, Gautam Vertika and Singh Ranjit, Quantitative Structure Activity Relationship and Design of Phenyl Alkyl Ketone Derivatives as Inhibitors of Phosphodiesterase 4, Current Enzyme Inhibition 2014; 10 (1) . https://dx.doi.org/10.2174/15734080113096660006
DOI https://dx.doi.org/10.2174/15734080113096660006 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
HIV-1, HCV and Alcohol in the CNS: Potential Interactions and Effects on Neuroinflammation
Current HIV Research Antihypertensive Therapy in Children: Differences in Medical Approach Between the United States and Europe
Current Medicinal Chemistry QSAR and Molecular Docking Techniques for the Discovery of Potent Monoamine Oxidase B Inhibitors: Computer-Aided Generation of New Rasagiline Bioisosteres
Current Topics in Medicinal Chemistry Organotypic Cultures as Tools for Testing Neuroactive Drugs – Link Between In-Vitro and In-Vivo Experiments
Current Medicinal Chemistry An Inventory of Short Term and Long Term Changes in Gene Expression Under Interferon β Treatment of Relapsing Remitting MS Patients
Current Pharmaceutical Design Biased Agonism as an Emerging Strategy in the Search for Better Opioid Analgesics
Current Medicinal Chemistry Prolyl Oligopeptidase, Inositol Phosphate Signalling and Lithium Sensitivity
CNS & Neurological Disorders - Drug Targets Healthy Diet and Reduction of Chronic Disease Risks of Night Shift Workers
Current Medicinal Chemistry Mechanism of Action of Methamphetamine within the Catecholamine and Serotonin Areas of the Central Nervous System
Current Drug Abuse Reviews Roles of p75NTR in Maintaining Brain Hemostasis and the Implications for p75NTR-targeted Therapies
Current Alzheimer Research Small Molecular Weight Inhibitors of Stress-Activated and Mitogen- Activated Protein Kinases
Mini-Reviews in Medicinal Chemistry Unfolded Protein Response and PERK Kinase as a New Therapeutic Target in the Pathogenesis of Alzheimer’s Disease
Current Medicinal Chemistry Natural Products as Promising Drug Candidates for the Treatment of Alzheimer’s Disease: Molecular Mechanism Aspect
Current Neuropharmacology In Vivo Electroporation of Gene Sequences for Therapeutic and Vaccination Applications
Recent Patents on DNA & Gene Sequences Endogenous Agmatine Inhibits Cerebral Vascular Matrix Metalloproteinases Expression by Regulating Activating Transcription Factor 3 and Endothelial Nitric Oxide Synthesis
Current Neurovascular Research Adrenoceptors: Non Conventional Target for Breast Cancer?
Current Medicinal Chemistry Role of Gap Junction Channel in the Development of Beat-to-Beat Action Potential Repolarization Variability and Arrhythmias
Current Pharmaceutical Design Issues in the Psychiatric Screening of Cancer Patients
Current Psychiatry Reviews Risperidone Microemulsion for Transnasal Delivery: Pharmacodynamic and Pharmacokinetic Evaluation
Pharmaceutical Nanotechnology Subject Index to Volume 5
Current Genomics